｜｜Linkou CGMH｜International Medicel Center｜Site map

Vertical Menu


Wing-Keen Yap

Primary appointment
Assistant Professor / Attending Physician, Department of Radiation Oncology, Linkou Chang Gung Memorial Hospital
  
Specialty
● Clinical Specialties: Head and Neck Cancer, Nasopharyngeal Carcinoma, Prostate Cancer, Urinary Tract Cancer, Esophageal Cancer, Hepatobiliary and Pancreatic Cancer, Sarcoma, and Rare Cancers (e.g., Eye Tumors)
● Technical Proficiencies: Proton Therapy, Image-Guided Intensity-Modulated Radiation Therapy (IG-IMRT), Stereotactic Radiosurgery (SRS), and Clinical Radiation Oncology
Education
MD, National Taiwan University, College of Medicine
Academic appointment &Employment record
● 2024 – Present: Assistant Professor & Attending Physician, Dept. of Radiation Oncology, Linkou Chang Gung Memorial Hospital
● 2021 – 2024: Instructor & Attending Physician, Dept. of Radiation Oncology, Linkou Chang Gung Memorial Hospital
● 2020 – 2021: Instructor & Attending Physician, Dept. of Radiation Oncology, Tucheng Chang Gung Memorial Hospital
● 2018 – 2020: Attending Physician, Dept. of Radiation Oncology, Linkou Chang Gung Memorial Hospital
● 2017 – 2018: Chief Resident, Dept. of Radiation Oncology, Linkou Chang Gung Memorial Hospital
● 2014 – 2017: Resident, Dept. of Radiation Oncology, Linkou Chang Gung Memorial Hospital
● 2013 – 2014: Post-Graduate Year (PGY) Resident, Far Eastern Memorial Hospital
● 2012 – 2013: Intern, National Taiwan University Hospital
Membership in Scientific and Medical Societies
● Certifications:
○ Board Certified in Radiation Oncology (Taiwan)
○ Medical License (Taiwan)
○ ECFMG Certified (United States Medical Licensing Examination)
● Societies:
○ Taiwan Society for Therapeutic Radiology and Oncology (TASTRO)
○ European Society for Radiotherapy and Oncology (ESTRO)
○ American Society for Radiotherapy and Oncology (ASTRO)
Licenses
Publication

Selected Peer-Reviewed Research

  • Yap WK, Lin CH, Hsu KH, Chen PY, Lin CY, Lin SN, Cheng NM, Chang KP, Kang CJ, Young CK, Liau CT, Lu YA, Hu YF, Yeh CC, Yeh TS, Tsai TY. Pretreatment nodal SUVmax predicts neck progression in hypopharyngeal cancer undergoing definitive chemoradiotherapy, while higher radiotherapy dose improves regional control particularly in the high SUV-N subgroup: a long-term outcome study. Am J Cancer Res. 2026;16(1):240-254.
  • Yap WK#, Cheng SC#, Lin CH, Hsiao IT, Tsai TY, Yap WL, Chen WP, Lin CY, Huang SM. An External Validation Study on Two Pre-Trained Large Language Models for Multimodal Prognostication in Laryngeal and Hypopharyngeal Cancer: Integrating Clinical, Treatment, and Radiomic Data to Predict Survival Outcomes with Interpretable Reasoning. Bioengineering (Basel). 2025 Dec 10;12(12):1345. doi: 10.3390/bioengineering12121345. PMID: 41463641; PMCID: PMC12729448.
  • Luan CW, Tsai YT, Chen KY, Yap WK*. Prognostic significance of estimated radiation dose to immune cells in cancer patients undergoing thoracic irradiation: A meta-analysis. Radiother Oncol. 2025 Nov;212:111123. doi: 10.1016/j.radonc.2025.111123. Epub 2025 Sep 6.
  • Yap WK, Lin CH, Hsu KH, Lin SN, Lin HC, Chang KP, Kang CJ, Hu YF, Shih MC, Tsai TY. Prognostic Value and Clinical Implication of Lymph Node-to-Primary Tumor SUV Ratio in Node-Positive Hypopharyngeal Squamous Cell Carcinoma Treated With Radiotherapy With or Without Chemotherapy. Clin Nucl Med. 2025 Jan 1;50(1):11-18. doi: 10.1097/RLU.0000000000005544. Epub 2024 Oct 17. PMID: 39441098.
  • Tsai TY#, Yap WK#, Wang TH, Lu YA, See A, Hu YF, Huang Y, Kao HK, Chang KP. Upfront Surgery Versus Upfront Concurrent Chemoradiotherapy as Primary Modality in Hypopharyngeal Squamous Cell Carcinoma: A Systematic Review and Meta-Analysis. J Otolaryngol Head Neck Surg. 2024 Jan-Dec;53:19160216241293633. doi: 10.1177/19160216241293633. PMID: 39468833; PMCID: PMC11528607.
  • Yap WK#, Hsu KH#, Wang TH, Lin CH, Kang CJ, Huang SM, Lin HC, Hung TM, Chang KP, Tsai TY. The prognostic value of lymph node to primary tumor standardized uptake value ratio in cancer patients: a meta-analysis. Ann Nucl Med. 2024 Aug;38(8):607-618. doi: 10.1007/s12149-024-01933-5. Epub 2024 May 9. PMID: 38724805.
  • Tsai TY, Chiang PC, Yap WK, Huang Y, See A, Hung SY, Lu CY, Lin CY, Chang TJ, Kao HK, Chang KP. Postoperative radiotherapy versus surgery alone in pN1 oral cavity cancer patients: A meta-analysis. Laryngoscope Investig Otolaryngol. 2024 May 15;9(3):e1260. doi: 10.1002/lio2.1260. PMID: 38751691; PMCID: PMC11094775.
  • Lin CH, Yan JL, Yap WK, Kang CJ, Chang YC, Tsai TY, Chang KP, Liao CT, Hsu CL, Chou WC, Wang HM, Huang PW, Fan KH, Huang BS, Tung-Chieh Chang J, Tu SJ, Lin CY. Prognostic value of interim CT-based peritumoral and intratumoral radiomics in laryngeal and hypopharyngeal cancer patients undergoing definitive radiotherapy. Radiother Oncol. 2023 Dec;189:109938. doi: 10.1016/j.radonc.2023.109938. Epub 2023 Oct 6. PMID: 37806562.
  • Yap WK, Hsiao IT, Yap WL, Tsai TY, Lu YA, Yang CK, Peng MT, Su EL, Cheng SC. A Radiotherapy Dose Map-Guided Deep Learning Method for Predicting Pathological Complete Response in Esophageal Cancer Patients after Neoadjuvant Chemoradiotherapy Followed by Surgery. Biomedicines. 2023 Nov 16;11(11):3072. doi: 10.3390/biomedicines11113072. PMID: 38002072; PMCID: PMC10669191.
  • Chou HD, Yap WK, Wang CC, Chao AN. Clinical outcomes of fiducial-free proton beam therapy in Asian patients with uveal melanoma. Clin Exp Ophthalmol. 2023 Nov;51(8):875-878. doi: 10.1111/ceo.14299. Epub 2023 Sep 24. PMID: 37743703.
  • Wu TH, Tsai YT, Chen KY, Yap WK*, Luan CW*. Utility of High-Sensitivity Modified Glasgow Prognostic Score in Cancer Prognosis: A Systemic Review and Meta-Analysis. Int J Mol Sci. 2023 Jan 10;24(2):1318. doi: 10.3390/ijms24021318. PMID: 36674837; PMCID: PMC9866297.
  • Yap WK, Shih MC, Chang YC, Lin CH, Huang SM, Tsai TY, Chang CF, Hsu CC, Tseng CK, Chen MF, Tsan DL, Liau CT, Hou MM, Chao YK, Chiu CH, Hung TM. Adjuvant Chemoradiotherapy Associated with Improved Overall Survival in Resected Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy in Intensity-Modulated Radiotherapy Era. Biomedicines. 2022 Nov 21;10(11):2989. doi: 10.3390/biomedicines10112989. PMID: 36428557; PMCID: PMC9687609.
  • Chiang YY, Chou YC, Chang KP, Liao CT, Wu YY, Yap WK, Pai PC, Chang JT, Lin CY, Fan KH, Huang BS, Hung TM, Tsang NM. Missed radiation therapy sessions in first three weeks predict distant metastasis and less favorable outcomes in surgically treated patients with oral cavity squamous cell carcinoma. Radiat Oncol. 2020 Aug 14;15(1):194. doi: 10.1186/s13014-020-01632-1. PMID: 32795324; PMCID: PMC7427928.
  • Lin YH, Huang SM, Yap WK, Yang JW, Yeung L, Tsan DL, Chang JT, Chen LC. Outcomes in patients with lacrimal gland carcinoma treated with definitive radiotherapy or eye-sparing surgery followed by adjuvant radiotherapy. Radiat Oncol. 2020 Jun 22;15(1):156. doi: 10.1186/s13014-020-01601-8. PMID: 32571366; PMCID: PMC7310012.
  • Chen PJ, Yap WK, Chang YC, Tseng CK, Chao YK, Hsieh JC, Pai PC, Lee CH, Yang CK, Ho AT, Hung TM. Prognostic value of lymph node to primary tumor standardized uptake value ratio in unresectable esophageal cancer. BMC Cancer. 2020 Jun 10;20(1):545. doi: 10.1186/s12885-020-07044-4. PMID: 32522275; PMCID: PMC7288503.
  • Lin CH, Hung TM, Chang YC, Hsieh CH, Shih MC, Huang SM, Yang CK, Chang CF, Chan SC, Yap WK*. Prognostic Value of Lymph Node-To-Primary Tumor Standardized Uptake Value Ratio in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy. Cancers (Basel). 2020 Mar 6;12(3):607. doi: 10.3390/cancers12030607. PMID: 32155748; PMCID: PMC7139766.
  • Huang SM, Chen YC, Chen WY, Yang LY, Tsan DL, Tsang NM, Yap WK, Tsai CS, Leung WM, Hong JH, Chang JT, Yeh TS, Wu TH, Chen YC, Lin YH, Huang BS. Optimal Timing for Postsurgical Adjuvant Therapy in Patients with Gastric Cancer: A Propensity Score Matching Study. J Cancer. 2019 Jan 1;10(2):332-340. doi: 10.7150/jca.27753. PMID: 30719127; PMCID: PMC6360315.
  • Yap WK, Shih MC, Kuo C, Pai PC, Chou WC, Chang KP, Tsai MH, Tsang NM. Development and Validation of a Nomogram for Assessing Survival in Patients With Metastatic Lung Cancer Referred for Radiotherapy for Bone Metastases. JAMA Netw Open. 2018 Oct 5;1(6):e183242. doi: 10.1001/jamanetworkopen.2018.3242. PMID: 30646236; PMCID: PMC6324455.
  • Yap WK, Chang YC, Hsieh CH, Chao YK, Chen CC, Shih MC, Hung TM. Favorable versus unfavorable prognostic groups by post-chemoradiation FDG-PET imaging in node-positive esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy. Eur J Nucl Med Mol Imaging. 2018 May;45(5):689-698. doi: 10.1007/s00259-017-3901-3. Epub 2017 Nov 30. PMID: 29188300.
  • Yap WK, Chang YC, Tseng CK, Hsieh CH, Chao YK, Su PJ, Hou MM, Yang CK, Pai PC, Lin CR, Hsieh CE, Wu YY, Hung TM. Predictive value of nodal maximum standardized uptake value of pretreatment [18F]fluorodeoxyglucose positron emission tomography imaging in patients with esophageal cancer. Dis Esophagus. 2017 Aug 1;30(8):1-10. doi: 10.1093/dote/dox021. PMID: 28575243.